omecamtiv mecarbil
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
As a novel cardiac myosin activator, Omecamtive Mecarbil (OM) has shown promising results in the management of systolic heart…
Heart failure continues to be a major global health problem with a pronounced impact on morbidity and mortality and very limited…
Introduction Current available inotropic agents increase cardiac contractility, but are associated with myocardial ischemia…
Omecamtiv mecarbil (OM) is a myosin activator agent developed for the treatment of heart failure. OM was reported to increase…
BACKGROUND
Clinical treatment of heart failure is still suffering from limited efficacy and unfavorable side effects. The…
This mini-review describes the Chemistry, Manufacturing and Control activities associated with the manufacture of [(14)C]-labeled…
Objective: Omecamtiv mecarbil is a novel small molecule that directly activates cardiac myosin and increases cardiac…
We certainly appreciate the swift response1 from the group of scientists who have put so much work into the development of…
Heart Failure continues to be a leading cause of mortality and morbidity worldwide. The dismal prognosis of patients in acute…
Acute heart failure represents an increasingly common cause of hospitalization, and may require the use of inotropic drugs in…